Skip to main content

Crown Bioscience 透過領先學術醫學中心獲得獨特模型來擴展 PDX 收集

Written by Customer Service on . Posted in Public Companies.

聖地牙哥, April 09, 2020 (GLOBE NEWSWIRE) — Crown Bioscience 今天宣佈透過與華盛頓大學及丹娜法伯癌症研究所的 CoMotion 達成新協議，以策略性擴展其患者衍生異種移植 (patient-derived xenograft, PDX) 收集。這些協議將分別為腫瘤藥物開發界提供急需的前列腺癌和淋巴瘤模型。
PDX 模型是目前轉移程度最大的臨床前體內模型，也是臨床前腫瘤藥物發現和開發的首選模型。但是，某些 PDX 可能很難從前列腺癌等特定適應症中獲取，而其他臨床相關的突變在目前 PDX 收集中的代表性不足。CrownBio 從華盛頓大學獲得 CoMotion 授權，將大幅增加市場上可用的前列腺癌 PDX 模型數量。LuCaP PDX 的新面板將增強 CrownBio 已建立的前列腺癌 PDX 收集，將提供廣泛的臨床相關模型，包括難以治療的去勢抵抗性前列腺癌，對阿比特龍和恩雜魯胺等標靶藥物具有耐藥性的 PDX，以及具有疾病模型相關的雄激素受體表達譜，包括 Arv7。與丹娜法伯癌症研究所的合作將廣泛的淋巴瘤帶入 CrownBio 的產品組合，包括 T/NK、套細胞和濾泡性淋巴瘤，以及難治或復發患者的 DLBCL。協議還包括納入常見藥物標靶的模型，例如具有 IDH1 突變的腦癌 PDX，以及含有發掘標靶藥物必需的受體酪氨酸激酶變化的 NSCLC SCC PDX。CrownBio 科研與創新副總裁 Davy Ouyang 表示：「透過這些令人興奮的協議，我們能夠為需要大量模型的研究領域提供功能完備的 PDX。CrownBio 作為 PDX 技術的全球領導者，早前已建立完善的基礎，透過增加這些功能，我們的西方模型收集將顯著增強，讓我們的全球客戶更易獲得最新的尖端模型。」現在，新模型將在 CrownBio 內部進行擴展，由生物庫進行儲存和表徵，然後再用於各種腫瘤學和免疫腫瘤學研究。這包括功效評估、小鼠臨床試驗、CAR-T 細胞療法評估、人源化和類器官發育。關於 Crown Bioscience Inc.Crown Bioscience 是一家 JSR 生命科學公司，是一家全球藥物研發和開發服務公司，提供轉化平台以推進腫瘤學、炎症和代謝疾病研究。憑著廣泛的相關模型和預測工具組合，Crown Bioscience 使客戶能夠提供優質的臨床候選人。如欲了解更多詳情，請瀏覽：https://www.crownbio.comhttps://www.jsrlifesciences.com關於華盛頓大學及 CoMotion華盛頓大學 (UW) 獲路透社評為全球最創新公立大學第一名，是聯邦資助研究的領先接受方，其創新成果具有改變世界的力量，從生物燃料替代品至用於治療腦退化症和腦癌的更有效治療方法，以及發展中國家的飲用水淨化技術。華盛頓大學的 CoMotion 是協作式創新樞紐，致力擴大華盛頓大學社區對全球經濟和社會的影響。透過開發並與本地和全球創新生態系統建立聯繫，CoMotion 幫助創新者從他們的想法和發現中發揮最大影響。
欲了解更多資訊，請瀏覽 https://comotion.uw.edu。傳媒查詢：Crown Bioscience
Jody Barbeau
Crown Bioscience Inc.
pr@crownbio.com華盛頓大學的 CoMotion
Donna O’Neill
donnao3@uw.edu

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.